242 related articles for article (PubMed ID: 14556940)
21. Effects of adrenal medulla graft on recovery of GABAergic and dopaminergic neuron deficits in mice: behavioural, pharmacological and immunohistochemical study.
Jousselin-Hosaja M; Tobin C; Venault P; Joubert C; Chapouthier G
Behav Brain Res; 2003 Mar; 140(1-2):185-93. PubMed ID: 12644291
[TBL] [Abstract][Full Text] [Related]
22. Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures.
Moy LY; Zeevalk GD; Sonsalla PK
J Neurochem; 2000 Apr; 74(4):1656-65. PubMed ID: 10737624
[TBL] [Abstract][Full Text] [Related]
23. Regulation of matrix metalloproteinase-9 gene expression in MPP+- or 6-OHDA-treated human neuroblastoma SK-N-BE(2)C cells.
Kim SY; Woo MS; Park JS; Kim HS
Neurochem Int; 2010 Feb; 56(3):437-42. PubMed ID: 19962414
[TBL] [Abstract][Full Text] [Related]
24. Changes in neuronal dopamine homeostasis following 1-methyl-4-phenylpyridinium (MPP+) exposure.
Choi SJ; Panhelainen A; Schmitz Y; Larsen KE; Kanter E; Wu M; Sulzer D; Mosharov EV
J Biol Chem; 2015 Mar; 290(11):6799-809. PubMed ID: 25596531
[TBL] [Abstract][Full Text] [Related]
25. Prevention of 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced nitration of tyrosine hydroxylase and neurotoxicity by EUK-134, a superoxide dismutase and catalase mimetic, in cultured dopaminergic neurons.
Pong K; Doctrow SR; Baudry M
Brain Res; 2000 Oct; 881(2):182-9. PubMed ID: 11036157
[TBL] [Abstract][Full Text] [Related]
26. C-terminal mechano growth factor protects dopamine neurons: a novel peptide that induces heme oxygenase-1.
Quesada A; Micevych P; Handforth A
Exp Neurol; 2009 Dec; 220(2):255-66. PubMed ID: 19735655
[TBL] [Abstract][Full Text] [Related]
27. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP
J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622
[TBL] [Abstract][Full Text] [Related]
28. Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice.
Ekue A; Boulanger JF; Morissette M; Di Paolo T
J Neuroendocrinol; 2002 Sep; 14(9):731-6. PubMed ID: 12213134
[TBL] [Abstract][Full Text] [Related]
29. Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels.
Vergo S; Johansen JL; Leist M; Lotharius J
Brain Res; 2007 Dec; 1185():18-32. PubMed ID: 18028884
[TBL] [Abstract][Full Text] [Related]
30. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL
Neurotoxicology; 2004 Sep; 25(5):761-9. PubMed ID: 15288507
[TBL] [Abstract][Full Text] [Related]
31. The role of membrane and vesicular monoamine transporters in the neurotoxic and hypothermic effects of 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH(2)-MPTP).
Numis AL; Unger EL; Sheridan DL; Chisnell AC; Andrews AM
Mol Pharmacol; 2004 Sep; 66(3):718-27. PubMed ID: 15322265
[TBL] [Abstract][Full Text] [Related]
32. L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice.
Reveron ME; Savelieva KV; Tillerson JL; McCormack AL; Di Monte DA; Miller GW
Neurotoxicology; 2002 Oct; 23(4-5):611-9. PubMed ID: 12428733
[TBL] [Abstract][Full Text] [Related]
33. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions.
Quesada A; Micevych PE
J Neurosci Res; 2004 Jan; 75(1):107-16. PubMed ID: 14689453
[TBL] [Abstract][Full Text] [Related]
34. Evidence for hydroxyl radical scavenging action of nitric oxide donors in the protection against 1-methyl-4-phenylpyridinium-induced neurotoxicity in rats.
Banerjee R; Saravanan KS; Thomas B; Sindhu KM; Mohanakumar KP
Neurochem Res; 2008 Jun; 33(6):985-95. PubMed ID: 17763941
[TBL] [Abstract][Full Text] [Related]
35. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
36. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
Väänänen AJ; Rauhala P; Tuominen RK; Liesi P
J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683
[TBL] [Abstract][Full Text] [Related]
37. RA410/Sly1 suppresses MPP+ and 6-hydroxydopamine-induced cell death in SH-SY5Y cells.
Bando Y; Katayama T; Taniguchi M; Ishibashi T; Matsuo N; Ogawa S; Tohyama M
Neurobiol Dis; 2005 Feb; 18(1):143-51. PubMed ID: 15649705
[TBL] [Abstract][Full Text] [Related]
38. Impairment of the neuronal dopamine transporter activity in MPP(+)-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors.
Barc S; Page G; Barrier L; Piriou A; Fauconneau B
Neurosci Lett; 2001 Nov; 314(1-2):82-6. PubMed ID: 11698152
[TBL] [Abstract][Full Text] [Related]
39. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Suzuki M; Desmond TJ; Albin RL; Frey KA
Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
[TBL] [Abstract][Full Text] [Related]
40. Functional identification and molecular cloning of a human brain vesicle monoamine transporter.
Erickson JD; Eiden LE
J Neurochem; 1993 Dec; 61(6):2314-7. PubMed ID: 8245983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
